Amber Trust

Amber Therapeutics is a clinical-stage biotechnology company focused on developing next-generation bioelectrical therapies for functional disorders. The company's lead program, Amber-UI, is a fully implantable closed-loop neuromodulation system designed to treat mixed urinary incontinence (MUI) by targeting the pudendal nerve. By utilizing a platform that can both sense and stimulate physiological signals, Amber aims to provide personalized, real-time therapy that adjusts to the patient's needs. The company is a spin-out from the University of Oxford and is currently advancing its technology through clinical feasibility studies.